Abstract B007: mychoiceTM User-Testing – Insights from diverse cancer patients
Authors: Fleisher Linda , Kenny Cassidy , Yeates Shayna Yeates , Landau Zoe , Kelly Patrick , Bass Sarah , Ammerman Diane , Bilgin Canan , Ma Esprit 
Published: January 2023

Abstract
(A) Although clinical trials (CTs) aim to establish new strategies for reducing cancer morbidity and mortality, participation remains suboptimal, especially for racial and ethnic minorities, and few studies have evaluated tailored communication tools to address barriers/facilitators to CT participation across diverse groups.(B) mychoiceTM is a novel, culturally tailored online CT education tool designed to foster shared decision making between patients (pts) and their providers. The mychoiceTM tool was developed over 5 years utilizing community engagement, perceptual mapping, a clinically based RCT, and in-depth user-testing (UX) which we will discuss further here. UX was conducted to further guide the implementation of mychoiceTM in routine clinical settings and to understand when is the ideal time for patients to receive CT education as well as obtain feedback on the tool’s content and usability. A mixed methods approach was utilized and included a talk-aloud walk through of the mychoiceTM tool, an in-depth interview targeting specific sections, and a post-survey. In order to maintain a representative sample, pts were contacted from reviewing their EMR data that met the enrollment criteria (age≥18 yrs, able to speak and read English, in active or completed treatment ≤ last 6 months), and CT participation status (participated in a CT, offered a CT but did not participate, or were never offered), race, and gender at Fox Chase Cancer Center and Temple University Health System. In total, 27 pts completed UX. 16 participants (59%) were non-white (NW), and nearly 90% of NW participants were black. Participants were 52% female, and 48% male, and split fairly evenly amongst CT participation status (26% participated, 37% offered but never participated, 37% never offered and never participated).(C) Preliminary results showed that responses were generally consistent between NW and W participants. Nearly all patients said that they would use mychoiceTM if it was given to them by their provider, and the majority of both groups (81% of NW pts and 64% of W pts) said that they would like to receive mychoiceTM prior to making a treatment decision. While all pts found that the tool would have been helpful with making a treatment decision, NW pts found the tool generally more helpful than W pts did. 56% of NW pts gave it a 5 (extremely helpful), while only 36% of W pts rated it the same. 45% of W pts gave it a 3 (moderately helpful), while only 36% of NW pts did. Patients across both groups recommended potential content additions including: additional information on side effects, cancer specific resources, and ways to find support which will be included in the next iteration.(D) While mychoiceTM was well received overall, preliminary findings show that the tool is particularly helpful among NW pts. These findings are consistent with those from the previously conducted RCT and will guide the next steps in the tools growing research initiatives and upcoming implementation study.
Citation Format: Linda Fleisher, Cassidy Kenny, Shayna Yeates Yeates, Zoe Landau, Patrick Kelly, Sarah Bass, Diane Ammerman, Canan Bilgin, Esprit Ma. mychoiceTM User-Testing – Insights from diverse cancer patients [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr B007.